Literature DB >> 9679761

Expression of CCKB/gastrin receptor isoforms in gastro-intestinal tumour cells.

S A Watson1, P A Clarke, A M Smith, A Varro, D Michaeli, S Grimes, M Caplin, J D Hardcastle.   

Abstract

Anti-serum raised against the human cholecystokinin B (CCKB)/gastrin receptor was used in Western blotting to differentiate the cellular locations of receptor isoforms expressed by human gastro-intestinal (GI) tumour cell lines. Using anti-serum directed against the amino-terminal extracellular tail of the CCKB/gastrin receptor, 8/9 cell lines were shown to express immunoreactive proteins of either m.w. 70 or 40 kDa, or both. Both isoforms were found to be associated with intracellular, non-nuclear membranes, whereas only the 70 kDa protein was expressed in the plasma membrane. Receptor expression was related to gastrin production and secretion. Both progastrin and glycine-extended gastrin-17 were produced and secreted by the tumour cell lines; however, carboxy amidated gastrin was not detected by radioimmunoassay. A CCKB/gastrin receptor transfectant NIH3T3 cell line did not produce detectable gastrin and showed exclusive expression of the 70 kDa receptor on the plasma membrane. One cell line had <50 pg/ml cell-associated progastrin and no detectable receptor form. Cell lines expressing 50-150 pg/ml had both 40 and 70 kDa receptor forms. Those expressing >150 pg/ml progastrin had only the 40 kDa isoform, which was shown to be exclusively expressed on intracellular, non-nuclear membranes, in one of the cell lines. Of the 4 cell lines exclusively expressing the lower m.w. receptor, 3 had gastrin present within the cell, which was not secreted. Thus, if cell-associated gastrin induces a proliferative effect, it may be by an intracrine pathway. Our study has identified the presence of CCKB/gastrin receptor isoforms in different cellular locations and may help toward understanding the complex autocrine and intracrine pathways mediated by gastrin peptides.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9679761     DOI: 10.1002/(sici)1097-0215(19980812)77:4<572::aid-ijc17>3.0.co;2-8

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Role of endogenous cholecystokinin on growth of human pancreatic cancer.

Authors:  Gail L Matters; Christopher McGovern; John F Harms; Kevin Markovic; Krystal Anson; Calpurnia Jayakumar; Melissa Martenis; Christina Awad; Jill P Smith
Journal:  Int J Oncol       Date:  2010-12-24       Impact factor: 5.650

2.  Gastrin is a target of the beta-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis.

Authors:  T J Koh; C J Bulitta; J V Fleming; G J Dockray; A Varro; T C Wang
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

3.  A comparison of the therapeutic effectiveness of gastrin neutralisation in two human gastric cancer models: relation to endocrine and autocrine/paracrine gastrin mediated growth.

Authors:  S A Watson; T M Morris; A Varro; D Michaeli; A M Smith
Journal:  Gut       Date:  1999-12       Impact factor: 23.059

4.  Localization of cholecystokinin receptor subtypes in the endocine pancreas.

Authors:  Jean Morisset; Sophie Julien; Jean Lainé
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

5.  Identification of novel growth factor-responsive genes in neuroendocrine gastrointestinal tumour cells.

Authors:  E Hofsli; L Thommesen; F Yadetie; M Langaas; W Kusnierczyk; U Falkmer; A K Sandvik; A Laegreid
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

6.  Germline Mutation of the CCK Receptor: A Novel Biomarker for Pancreas Cancer.

Authors:  Jelal Alsubai; Gail L Matters; Christopher O McGovern; Jiangang Liao; Evan L Gilius; Jill P Smith
Journal:  Clin Transl Gastroenterol       Date:  2016-01-07       Impact factor: 4.488

7.  Potential role of endocrine gastrin in the colonic adenoma carcinoma sequence.

Authors:  S A Watson; T M Morris; D F McWilliams; J Harris; S Evans; A Smith; P A Clarke
Journal:  Br J Cancer       Date:  2002-08-27       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.